MARKET

CERS

CERS

Cerus
NASDAQ
3.700
-0.160
-4.15%
After Hours: 3.680 -0.02 -0.54% 16:43 11/28 EST
OPEN
3.740
PREV CLOSE
3.860
HIGH
3.875
LOW
3.670
VOLUME
935.85K
TURNOVER
0
52 WEEK HIGH
7.20
52 WEEK LOW
3.250
MARKET CAP
656.46M
P/E (TTM)
-16.9414
1D
5D
1M
3M
1Y
5Y
Cerus's Return On Capital Employed Overview
Benzinga · 11/21 14:48
Cerus Corporation to Participate in Upcoming Investor Conferences
CONCORD, Calif., November 04, 2022--Cerus Corporation (Nasdaq: CERS) announced today that Vivek Jayaraman, Cerus’ chief operating officer, is scheduled to participate in two conferences:
Business Wire · 11/04 12:00
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of 0% and 1.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/03 21:55
Cerus GAAP EPS of -$0.05 beats by $0.01, revenue of $46.34M beats by $6.22M
Seekingalpha · 11/03 20:33
Cerus Q3 EPS $(0.05) Beats $(0.06) Estimate, Sales $39.57M Miss $44.55M Estimate
Benzinga · 11/03 20:01
Cerus Corporation Announces Third Quarter Financial Results
CONCORD, Calif., November 03, 2022--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2022.
Business Wire · 11/03 20:00
-- Earnings Flash (CERS) CERUS CORPORATION Posts Q3 Revenue $46.3M, vs. Street Est of $40.6M
-- Earnings Flash (CERS) CERUS CORPORATION Posts Q3 Revenue $46.3M, vs. Street Est of $40.6M
MT Newswires · 11/03 16:09
Cerus Gets $9.1 Million Funding to Develop Product for Trauma-Related Bleeding
Cerus Gets $9.1 Million Funding to Develop Product for Trauma-Related Bleeding
MT Newswires · 11/02 14:39
More
About CERS
Cerus Corporation is a biomedical products company. It is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

Webull offers kinds of Cerus Corporation stock information, including NASDAQ:CERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CERS stock methods without spending real money on the virtual paper trading platform.